reports
Resolutions of Annual Geneal Meeting
Resolutions of Annual Geneal Meeting April 30, 2024Announcement no. 10 Resolutions of Annual Geneal Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, April 30, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today held its Annual General Meeting with the following results: ITEM 1 - The Board's report on the Company’s activities during the past year was noted by the Annual General Meeting. ITEM 2 – The annual report was approved by the Annual General Meeting ...
Grant of warrants
Grant of warrants 23 April 2024Announcement no. 9 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 23, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 4,000,000 warrants to members of the Executive Management. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.23 per share, corresponding to the closing price today on ...
BioPorto A/S Appoints Chief Legal Officer
BioPorto A/S Appoints Chief Legal Officer April 10, 2024Announcement no. 8 BioPorto A/S Appoints Chief Legal Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 10, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the appointment of Gry Louise Husby Larsen as its new Executive Vice President and Chief Legal Officer (CLO), and member of the Executive Management team as of April 15, 2024. Gry Louise Husby Larsen has been employed...
New Board Candidate for the upcoming Annual Geneal Meeting
New Board Candidate for the upcoming Annual Geneal Meeting April 5, 2024Announcement no. 7 New Board Candidate for the upcoming Annual Geneal Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, April 5, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that the Company has received notice that Tonni Bülow-Nielsen, due to personal reasons, will not be a candidate for the upcoming general meeting on 30 April 2024. In addition to the remaining candida...
Notice convening the Annual General Meeting in BioPorto A/S
Notice convening the Annual General Meeting in BioPorto A/S April 4, 2024Announcement no. 6 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: Tuesday April 30, 2024, at 3.00 p.m. (CEST)At the Company’s addressTuborg Havnevej 15, st., DK-2900 Hellerup, Denmark AGENDA: ITEM 1 - REPORT ON THE COMPANY’S ACTIVITIES DURING THE PAST YEAR The Board of Directors proposes that the Board's report on the Company’s activities for the pas...
Correction: BioPorto Announces Annual Results for 2023
Correction: BioPorto Announces Annual Results for 2023 Correction: Updated Annual Report attached April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today financial results for the year ended December 31, 2023. Highlights 2023 Revenue and adjusted EBITDA in 2023 are in line with the preliminary results ann...
BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executi...
BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer April 2, 2024Announcement no. 04 BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 2, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the appointment of Peter Mørch Eriksen as permanent Group CEO of BioPorto. Peter Mørch Eriksen was appointed as interim CEO of BioPorto in January 2024. ...
BioPorto announces preliminary results for 2023 and provides strategic...
BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 February 22, 2024 Announcement no. 03 BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 COPENHAGEN, DENMARK and BOSTON, MA, February 22, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), today announced its preliminary results for 2023 and described its strategy and expectations for 2024-2026 and beyond. Securing FDA clearance and meeting financial targets in 2023 In December 2023, BioPorto passed...
Roche Diagnostics and BioPorto expand collaboration
Roche Diagnostics and BioPorto expand collaboration 20 February 20, 2024Announcement no. 02 Roche Diagnostics and BioPorto expand collaboration COPENHAGEN, DENMARK and BOSTON, MA, 20 February, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has today announced an expansion of its strategic collaboration with Roche Diagnostics. As announced on December 7, 2023, BioPorto received FDA clearance in the US for its NGAL test to be marketed as ProNephro AKI™ (NGAL) on Roche’s cobas® c 501. ProNephro AKI (NGAL) is the first Acute Kidney Injury (AKI) biomarker tes...
BioPorto implements changes to the Executive Management.
BioPorto implements changes to the Executive Management. January 9, 2024 Announcement no. 01 BioPorto implements changes to the Executive Management. COPENHAGEN, DENMARK and BOSTON, MA, January 9, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), today announced changes to the Executive Management. By mutual agreement, BioPorto’s CEO, Anthony Pare, is stepping down and leaving BioPorto with effect from today. Peter Mørch Eriksen has been appointed as interim CEO. Chairman John McDonough says: “We are excited to have achieved FDA clearance for pediatric us...
Bioporto A S: 1 director
A director at Bioporto A S sold 246,224 shares at 3.201DKK and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Managers’ transactions
Managers’ transactions December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family ...
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United Sta...
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years December 7, 2023 Announcement no. 20 BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United StatesFirst Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years COPENHAGEN, DENMARK and BOSTON, MA, December 7, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), today announced receipt of a US Food and Drug Administration (FDA) 510(k) clearance for BioPorto’s NGAL test, to be...
Resignation of Director
Resignation of Director December 4, 2023Announcement no. 19 Resignation of Director COPENHAGEN, DENMARK and BOSTON, MA, USA, December 4, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) announced today that Jan Leth Christensen has informed the Company that he has decided to resign from his position as a board member for BioPorto. The search for a successor with relevant expertise, including familiarity with public company practices in the Nordics, will be initiated and a new candidate is expected to be proposed in connection with the Company’s Annual G...
BioPorto Announces Interim Results and Business Update For the Third Q...
BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023 November 1, 2023Announcement no. 18 BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023 COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results and business updates for the third quarter and nine months of fiscal 2023. Recent Highlights For the first nine months ending September 30, 2023: ...
BioPorto provides interim Q3 results and revised 2023 Financial Guidan...
BioPorto provides interim Q3 results and revised 2023 Financial Guidance. October 31, 2023Announcement no. 17 BioPorto provides interim Q3 results and revised 2023 Financial Guidance. COPENHAGEN, Denmark and BOSTON, MA, USA, October 31, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced a change in the Company’s 2023 financial guidance and interim results for the first nine months and third quarter of fiscal year 2023. Interim Results For the third quarter ending September 30, 2023: Total revenue of DKK 8.6 million / USD 1.3 million, a 63% increase over...
Grant of Warrants
Grant of Warrants September 22, 2023Announcement no. 16 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, September 22, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 700,000 warrants to members of the Board of Directors of the Company, and further to issue a total of 2,750,000 warrants to employees of the BioPorto group. Each warrant grants the holder the right to subscribe for one share in BioPorto. The e...
BioPorto Initiates Search for new CFO as Neil Goldman Resigns
BioPorto Initiates Search for new CFO as Neil Goldman Resigns September 19, 2023Announcement no. 15 BioPorto Initiates Search for new CFO as Neil Goldman Resigns COPENHAGEN, DENMARK and BOSTON, MA, USA, September 19, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) announced today that Neil Goldman has informed the Company that he has decided to resign to take up the CFO position at another company. The search for a successor will be initiated and Neil Goldman will assist with the transition until a date to be determined. “I have valued the...
BioPorto Announces Interim Results for the First Six Months of 2023
BioPorto Announces Interim Results for the First Six Months of 2023 August 1, 2023Announcement no. 14 BioPorto Announces Interim Results for the First Six Months of 2023 COPENHAGEN, Denmark and BOSTON, MA, USA, August 1, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first six months of 2023 and business progress for the second quarter of 2023. Recent Highlights For the six months ending June 30, 2023: Total revenue of DKK 15.8 million / USD 2.3 million, a 5% increase over the prior yearAdjusted EBITDA of DKK (31.5) milli...
Managers’ transactions
Managers’ transactions June 28, 2023Announcement no. 13 Managers’ transactions In connection with the completion of BioPorto A/S’ rights issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them. 1. Details of the person discharging managerial res...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.